Corporate
Profile

Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.
See Japanese corporate profile

Latest update： 30/07/2021 15:25:19

Kankyo Daizen Co.,Ltd. 

From development of deodorizing products using "Zendama Kassei Sui" to land improvement and environmental conservation projects

We manufacture and sell deodorizers, soil enhancers, and other products. We use bovine urine, which is a source of pollution, as a raw material to we manufacture "Zendama Kassei Sui" activated solution with benign ingredients using our unique microbial fermentation technology. We then process this activated solution and distribute it as a deodorizer or soil enhancer.

Inquiry

Overview

Corporate name Kankyo Daizen Co.,Ltd.
Representative Makoto Kubonouchi
Corporate website http://www.kankyo-daizen.jp/
Capital 10,000,000 Yen
Number of Employees 18 (Number of full-time employees: 18)
Established date 02, 2006
Head office: Country Japan
Head office: Address 438-7 Tannocho 3-ku, Kitami-shi,, Hokkaido, 099-2103
Industry Manufacture of chemical and allied products
Main phone number 0157676788

Client & Business location info

Key Production Center (Factory) Head Office and Works
Support organization Organization for Small & Medium Enterprises and Regional Innovation, JAPAN, Hokkaido Head Office
Inquiry

Similar Companies

HEALTH BEAUTY Co., Ltd.
Planning and development capabilities Quality control
GS Alliance Co., Ltd.
We conduct R&D of state-of-the-art technologies in the energy and environmental fields. This includes biodegradable plastics, cellulose nanofibers, next-generation secondary batteries (all-solid-state lithium-ion batteries, aluminum batteries, etc.), bioethanol from non-edible plants, quantum dots, and Metal-Organic Frameworks.
MEDRx Co., Ltd
We are focusing on applying our core technologies to the development of formulations that take advantage of the benefits of transdermal administration (avoidance of first-pass effects, adjustment of administration time, improvement of medication adherence, and so on) and also solve the hurdles of existing technologies (skin absorption improvement, PK profile improvement, biological drug administration, and so on). We specialize in developing transdermal formulations of drugs that match the advantages of transdermal administration, drugs that are difficult to administer transdermally, or drugs that do not fully utilize their potential through oral or other routes of administration.